{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:02:42Z","timestamp":1790690562378,"version":"4.1.0"},"reference-count":76,"publisher":"Harborside Press, LLC","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:p>Vulvovaginal melanomas are rare cancers of the vulva and vagina that are often treated similarly despite important differences. Furthermore, although these melanomas are generally considered mucosal, due to their rarity and limited clinical trial data and level I evidence they are often treated with cutaneous melanoma strategies. Resection of the tumor, with or without lymph node assessment, is the preferred primary treatment approach for these cancers. Breslow thickness is a main determinant of surgical approach, and a negative excision margin should be the goal, if possible, without pelvic exenteration. The advent of targeted therapies and immunotherapies has led to new standards in the adjuvant setting, with potential in the neoadjuvant setting as well; however, there is a strong need for mucosal and vulvovaginal melanoma\u2013specific trials and data to guide treatment, and trial participation should be recommended for all patients with these cancers.<\/jats:p>","DOI":"10.6004\/jnccn.2025.7081","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T12:31:25Z","timestamp":1773318685000},"source":"Crossref","is-referenced-by-count":4,"title":["Modern Management of Newly Diagnosed Vulvovaginal Melanoma"],"prefix":"10.6004","volume":"24","author":[{"given":"Mario M.","family":"Leitao","sequence":"first","affiliation":[{"name":"Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"Department of Obstetrics and Gynecology, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","article-title":"Cancer of the vulva","author":"Kosary CL","year":"2007","unstructured":"Kosary CL. Cancer of the vulva. In: Ries LAG, Young JL, Keel GE, et al, eds. SEER Survival Monograph: Cancer Survival Among Adults: US SEER Program 1988\u20132001, Patient and Tumor Characteristics. National Cancer Institute, SEER Program, NIH Pub. No. 07-6215; 2007:147\u2013153."},{"key":"B2","article-title":"Cancer of the vagina","author":"Kosary CL","year":"2007","unstructured":"Kosary CL. Cancer of the vagina. In: Ries LAG, Young JL, Keel GE, et al, eds. SEER Survival Monograph: Cancer Survival Among Adults: US SEER Program 1988\u20132001, Patient and Tumor Characteristics. National Cancer Institute, SEER Program, NIH Pub. No. 07-6215; 2007:155\u2013158."},{"key":"B3","series-title":"Am J Clin Dermatol","first-page":"285","article-title":"Malignant melanoma of the vulva and vagina: a US population-based study of 1863 patients","volume":"21","author":"Wohlmuth C","year":"2020","unstructured":"Wohlmuth C, Wohlmuth-Wieser I, May T,  Malignant melanoma of the vulva and vagina: a US population-based study of 1863 patients. Am J Clin Dermatol 2020;21:285\u2013295."},{"key":"B4","series-title":"Cancer","first-page":"1333","article-title":"Vulvar and vaginal melanoma: a unique subclass of mucosal melanoma based on comprehensive molecular analysis of 51 cases compared to 2253 cases of nongynecologic melanoma","volume":"123","author":"Hou JY","year":"2017","unstructured":"Hou JY, Baptiste C, Hombalegowda RB,  Vulvar and vaginal melanoma: a unique subclass of mucosal melanoma based on comprehensive molecular analysis of 51 cases compared to 2253 cases of nongynecologic melanoma. Cancer 2017;123:1333\u20131344."},{"key":"B5","article-title":"NCCN Clinical Practice Guidelines in Oncology: Melanoma: Cutaneous. Version 2.2023","author":"Swetter SM","unstructured":"Swetter SM, Johnson D, Albertini MR,  NCCN Clinical Practice Guidelines in Oncology: Melanoma: Cutaneous. Version 2.2023. Accessed September 26, 2023. To view the most recent version, visit https:\/\/www.nccn.org"},{"key":"B6","series-title":"Clin Cancer Res","first-page":"2093","article-title":"Tumor thickness and mitotic rate robustly predict melanoma-specific survival in patients with primary vulvar melanomas: a retrospective review of 100 cases","volume":"23","author":"Nagarajan P","year":"2017","unstructured":"Nagarajan P, Curry JL, Ning J,  Tumor thickness and mitotic rate robustly predict melanoma-specific survival in patients with primary vulvar melanomas: a retrospective review of 100 cases. Clin Cancer Res 2017;23:2093\u20132104."},{"key":"B7","series-title":"Ann Surg","first-page":"262","article-title":"Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm)","volume":"218","author":"Balch CM","year":"1993","unstructured":"Balch CM, Urist MM, Karakousis CP,  Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Ann Surg 1993;218:262\u2013269."},{"key":"B8","series-title":"Ann Surg Oncol","first-page":"101","article-title":"Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas","volume":"8","author":"Balch CM","year":"2001","unstructured":"Balch CM, Soong S, Smith T,  Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol 2001;8:101\u2013108."},{"key":"B9","series-title":"Ann Surg Oncol","first-page":"4050","article-title":"A phase III, multicenter, randomized controlled trial investigating 1-cm versus 2-cm surgical excision margins for stage II primary cutaneous melanoma (MelMarT-II)","volume":"29","author":"Rossi AJ","year":"2022","unstructured":"Rossi AJ, Verbus EA, Faries MB,  A phase III, multicenter, randomized controlled trial investigating 1-cm versus 2-cm surgical excision margins for stage II primary cutaneous melanoma (MelMarT-II). Ann Surg Oncol 2022;29:4050\u20134051."},{"key":"B10","series-title":"Ann Surg Oncol","first-page":"1959","article-title":"Melanoma of the vulva and vagina: principles of staging and their relevance to management based on a clinicopathologic analysis of 85 cases","volume":"22","author":"Seifried S","year":"2015","unstructured":"Seifried S, Haydu LE, Quinn MJ,  Melanoma of the vulva and vagina: principles of staging and their relevance to management based on a clinicopathologic analysis of 85 cases. Ann Surg Oncol 2015;22:1959\u20131966."},{"key":"B11","series-title":"Gynecol Oncol","first-page":"147","article-title":"Patient-reported outcomes after surgery for endometrial carcinoma: prevalence of lower-extremity lymphedema after sentinel lymph node mapping versus lymphadenectomy","volume":"156","author":"Leitao MM","year":"2020","unstructured":"Leitao MM, Zhou QC, Gomez-Hidalgo NR,  Patient-reported outcomes after surgery for endometrial carcinoma: prevalence of lower-extremity lymphedema after sentinel lymph node mapping versus lymphadenectomy. Gynecol Oncol 2020;156:147\u2013153."},{"key":"B12","series-title":"J Clin Oncol","first-page":"884","article-title":"Sentinel node dissection is safe in the treatment of early-stage vulvar cancer","volume":"26","author":"Van der Zee AGJ","year":"2008","unstructured":"Van der Zee AGJ, Oonk MH, De Hullu JA,  Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. J Clin Oncol 2008;26:884\u2013889."},{"key":"B13","series-title":"J Natl Compr Canc Netw","first-page":"364","article-title":"NCCN Guidelines Insights: Melanoma: Cutaneous, Version 2.2021","volume":"19","author":"Swetter SM","year":"2021","unstructured":"Swetter SM, Thompson JA, Albertini MR,  NCCN Guidelines Insights: Melanoma: Cutaneous, Version 2.2021. J Natl Compr Canc Netw 2021;19:364\u2013376."},{"key":"B14","series-title":"N Engl J Med","first-page":"1307","article-title":"Sentinel-node biopsy or nodal observation in melanoma","volume":"355","author":"Morton DL","year":"2006","unstructured":"Morton DL, Thompson JF, Cochran AJ,  Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006;355:1307\u20131317."},{"key":"B15","series-title":"N Engl J Med","first-page":"599","article-title":"Final trial report of sentinel-node biopsy versus nodal observation in melanoma","volume":"370","author":"Morton DL","year":"2014","unstructured":"Morton DL, Thompson JF, Cochran AJ,  Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med 2014;370:599\u2013609."},{"key":"B16","series-title":"N Engl J Med","first-page":"2211","article-title":"Completion dissection or observation for sentinel-node metastasis in melanoma","volume":"376","author":"Faries MB","year":"2017","unstructured":"Faries MB, Thompson JF, Cochran AJ,  Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med 2017;376:2211\u20132222."},{"key":"B17","series-title":"J Clin Oncol","first-page":"3000","article-title":"Final analysis of DeCOG-SLT trial: no survival benefit for complete lymph node dissection in patients with melanoma with positive sentinel node","volume":"37","author":"Leiter U","year":"2019","unstructured":"Leiter U, Stadler R, Mauch C,  Final analysis of DeCOG-SLT trial: no survival benefit for complete lymph node dissection in patients with melanoma with positive sentinel node. J Clin Oncol 2019;37:3000\u20133008."},{"key":"B18","series-title":"Lancet","first-page":"1718","article-title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomized, double-blind, phase 3 trial","volume":"399","author":"Luke JJ","year":"2022","unstructured":"Luke JJ, Rutkowski P, Queirolo P,  Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomized, double-blind, phase 3 trial. Lancet 2022;399:1718\u20131729."},{"key":"B19","series-title":"Lancet Oncol","first-page":"1378","article-title":"Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomized, phase 3 trial","volume":"23","author":"Long GV","year":"2022","unstructured":"Long GV, Luke J, Khattak MA,  Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomized, phase 3 trial. Lancet Oncol 2022;23:1378\u20131388."},{"key":"B20","series-title":"Clin Cancer Res","first-page":"4488","article-title":"Phase II randomized trial comparing high-dose IFN-\u03b12b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma","volume":"19","author":"Lian B","year":"2013","unstructured":"Lian B, Si L, Cui C,  Phase II randomized trial comparing high-dose IFN-\u03b12b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma. Clin Cancer Res 2013;19:4488\u20134498."},{"key":"B21","series-title":"Ann Oncol","first-page":"1061","article-title":"Toripalimab (anti-PD-1) versus high-dose interferon-\u03b12b as adjuvant therapy in resected mucosal melanoma: a phase II randomized trial","volume":"33","author":"Lian B","year":"2022","unstructured":"Lian B, Si L, Chi ZH,  Toripalimab (anti-PD-1) versus high-dose interferon-\u03b12b as adjuvant therapy in resected mucosal melanoma: a phase II randomized trial. Ann Oncol 2022;33:1061\u20131070."},{"key":"B22","series-title":"N Engl J Med","first-page":"1845","article-title":"Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy","volume":"375","author":"Eggermont AMM","year":"2016","unstructured":"Eggermont AMM, Chiarion-Sileni V, Grob JJ,  Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med 2016;375:1845\u20131855."},{"key":"B23","series-title":"J Clin Oncol","first-page":"567","article-title":"Phase III study of adjuvant ipilimumab (3 or 10 mg\/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma: North American Intergroup E1609","volume":"38","author":"Tarhini AA","year":"2020","unstructured":"Tarhini AA, Lee SJ, Hodi S,  Phase III study of adjuvant ipilimumab (3 or 10 mg\/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma: North American Intergroup E1609. J Clin Oncol 2020;38:567\u2013575."},{"key":"B24","series-title":"N Engl J Med","first-page":"1824","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber J","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M,  Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med 2017;377:1824\u20131835."},{"key":"B25","series-title":"Lancet Oncol","first-page":"1465","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB-IIIC and stage IV melanoma (CheckMate 238): 4-year results from a multicenter, double-blind, randomized controlled, phase III trial","volume":"21","author":"Ascierto PA","year":"2020","unstructured":"Ascierto PA, Del Vecchio M, Mandala M,  Adjuvant nivolumab versus ipilimumab in resected stage IIIB-IIIC and stage IV melanoma (CheckMate 238): 4-year results from a multicenter, double-blind, randomized controlled, phase III trial. Lancet Oncol 2020;21:1465\u20131477."},{"key":"B26","series-title":"J Clin Oncol","first-page":"3925","article-title":"Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: updated results from the EORTC 1325-MG\/KEYNOTE-054 trial","volume":"38","author":"Eggermont AMM","year":"2020","unstructured":"Eggermont AMM, Blank CU, Mandala M,  Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: updated results from the EORTC 1325-MG\/KEYNOTE-054 trial. J Clin Oncol 2020;38:3925\u20133936."},{"key":"B27","series-title":"N Engl J Med","first-page":"1139","article-title":"Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma","volume":"383","author":"Dummer R","year":"2020","unstructured":"Dummer R, Hauschild A, Santinami M,  Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma. N Engl J Med 2020;383:1139\u20131148."},{"key":"B28","series-title":"Ann Oncol","first-page":"1631","article-title":"Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E\/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study","volume":"28","author":"Long GV","year":"2017","unstructured":"Long GV, Flaherty KT, Stroyakovskiy D,  Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E\/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol 2017;28:1631\u20131639."},{"key":"B29","series-title":"J Surg Oncol","first-page":"111","article-title":"Does metastasectomy improve survival in patients with stage IV melanoma? A cancer registry analysis of outcomes","volume":"104","author":"Wasif N","year":"2011","unstructured":"Wasif N, Bagaria SP, Ray P,  Does metastasectomy improve survival in patients with stage IV melanoma? A cancer registry analysis of outcomes. J Surg Oncol 2011;104:111\u2013115."},{"key":"B30","series-title":"Ann Surg Oncol","first-page":"2547","article-title":"Metastasectomy for distant metastatic melanoma: analysis of data from the First Mulitcenter Selective Lymphadenectomy Trial (MSLT-I)","volume":"19","author":"Howard JH","year":"2012","unstructured":"Howard JH, Thompson JF, Mozzillo N,  Metastasectomy for distant metastatic melanoma: analysis of data from the First Mulitcenter Selective Lymphadenectomy Trial (MSLT-I). Ann Surg Oncol 2012;19:2547\u20132555."},{"key":"B31","series-title":"Cancer","first-page":"4740","article-title":"A phase 2 trial of complete resection for stage IV melanoma","volume":"117","author":"Sosman JA","year":"2011","unstructured":"Sosman JA, Moon J, Tuthill RJ,  A phase 2 trial of complete resection for stage IV melanoma. Cancer 2011;117:4740\u20134746."},{"key":"B32","series-title":"Ann Surg Oncol","first-page":"5005","article-title":"Surgical utilization and outcomes for patients with stage IV melanoma in the modern immunotherapy era","volume":"30","author":"Lwin TM","year":"2023","unstructured":"Lwin TM, Kaelberer Z, Ruan M,  Surgical utilization and outcomes for patients with stage IV melanoma in the modern immunotherapy era. Ann Surg Oncol 2023;30:5005\u20135012."},{"key":"B33","series-title":"Nat Med","first-page":"1655","article-title":"Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma","volume":"24","author":"Blank CU","year":"2018","unstructured":"Blank CU, Rozeman EA, Fanchi LF,  Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med 2018;24:1655\u20131661."},{"key":"B34","series-title":"Lancet Oncol","first-page":"948","article-title":"Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial","volume":"20","author":"Rozeman EA","year":"2019","unstructured":"Rozeman EA, Menzies AM, van Akkooi ACJ,  Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol 2019;20:948\u2013960."},{"key":"B35","series-title":"Ann Oncol","first-page":"420","article-title":"Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials","volume":"34","author":"Versluis JM","year":"2023","unstructured":"Versluis JM, Menzies AM, Sikorska K,  Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials. Ann Oncol 2023;34:420\u2013430."},{"key":"B36","series-title":"Nat Med","first-page":"1649","article-title":"Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma","volume":"24","author":"Amaria RN","year":"2018","unstructured":"Amaria RN, Reddy SM, Tawbi HA,  Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med 2018;24:1649\u20131654."},{"key":"B37","series-title":"N Engl J Med","first-page":"813","article-title":"Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma","volume":"388","author":"Patel SP","year":"2023","unstructured":"Patel SP, Othus M, Chen Y,  Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. N Engl J Med 2023;388:813\u2013823."},{"key":"B38","series-title":"Gynecol Oncol Rep","first-page":"42","article-title":"Combined immunotherapy and radiation for treatment of mucosal melanomas of the lower genital tract","volume":"16","author":"Schiavone MB","year":"2016","unstructured":"Schiavone MB, Broach V, Shoushtari AN,  Combined immunotherapy and radiation for treatment of mucosal melanomas of the lower genital tract. Gynecol Oncol Rep 2016;16:42\u201346."},{"key":"B1","article-title":"Cancer of the vulva","author":"Kosary CL","year":"2007","unstructured":"Kosary CL. Cancer of the vulva. In: Ries LAG, Young JL, Keel GE, et al, eds. SEER Survival Monograph: Cancer Survival Among Adults: US SEER Program 1988\u20132001, Patient and Tumor Characteristics. National Cancer Institute, SEER Program, NIH Pub. No. 07-6215; 2007:147\u2013153."},{"key":"B2","article-title":"Cancer of the vagina","author":"Kosary CL","year":"2007","unstructured":"Kosary CL. Cancer of the vagina. In: Ries LAG, Young JL, Keel GE, et al, eds. SEER Survival Monograph: Cancer Survival Among Adults: US SEER Program 1988\u20132001, Patient and Tumor Characteristics. National Cancer Institute, SEER Program, NIH Pub. No. 07-6215; 2007:155\u2013158."},{"key":"B3","series-title":"Am J Clin Dermatol","first-page":"285","article-title":"Malignant melanoma of the vulva and vagina: a US population-based study of 1863 patients","volume":"21","author":"Wohlmuth C","year":"2020","unstructured":"Wohlmuth C, Wohlmuth-Wieser I, May T,  Malignant melanoma of the vulva and vagina: a US population-based study of 1863 patients. Am J Clin Dermatol 2020;21:285\u2013295."},{"key":"B4","series-title":"Cancer","first-page":"1333","article-title":"Vulvar and vaginal melanoma: a unique subclass of mucosal melanoma based on comprehensive molecular analysis of 51 cases compared to 2253 cases of nongynecologic melanoma","volume":"123","author":"Hou JY","year":"2017","unstructured":"Hou JY, Baptiste C, Hombalegowda RB,  Vulvar and vaginal melanoma: a unique subclass of mucosal melanoma based on comprehensive molecular analysis of 51 cases compared to 2253 cases of nongynecologic melanoma. Cancer 2017;123:1333\u20131344."},{"key":"B5","article-title":"NCCN Clinical Practice Guidelines in Oncology: Melanoma: Cutaneous. Version 2.2023","author":"Swetter SM","unstructured":"Swetter SM, Johnson D, Albertini MR,  NCCN Clinical Practice Guidelines in Oncology: Melanoma: Cutaneous. Version 2.2023. Accessed September 26, 2023. To view the most recent version, visit https:\/\/www.nccn.org"},{"key":"B6","series-title":"Clin Cancer Res","first-page":"2093","article-title":"Tumor thickness and mitotic rate robustly predict melanoma-specific survival in patients with primary vulvar melanomas: a retrospective review of 100 cases","volume":"23","author":"Nagarajan P","year":"2017","unstructured":"Nagarajan P, Curry JL, Ning J,  Tumor thickness and mitotic rate robustly predict melanoma-specific survival in patients with primary vulvar melanomas: a retrospective review of 100 cases. Clin Cancer Res 2017;23:2093\u20132104."},{"key":"B7","series-title":"Ann Surg","first-page":"262","article-title":"Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm)","volume":"218","author":"Balch CM","year":"1993","unstructured":"Balch CM, Urist MM, Karakousis CP,  Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Ann Surg 1993;218:262\u2013269."},{"key":"B8","series-title":"Ann Surg Oncol","first-page":"101","article-title":"Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas","volume":"8","author":"Balch CM","year":"2001","unstructured":"Balch CM, Soong S, Smith T,  Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol 2001;8:101\u2013108."},{"key":"B9","series-title":"Ann Surg Oncol","first-page":"4050","article-title":"A phase III, multicenter, randomized controlled trial investigating 1-cm versus 2-cm surgical excision margins for stage II primary cutaneous melanoma (MelMarT-II)","volume":"29","author":"Rossi AJ","year":"2022","unstructured":"Rossi AJ, Verbus EA, Faries MB,  A phase III, multicenter, randomized controlled trial investigating 1-cm versus 2-cm surgical excision margins for stage II primary cutaneous melanoma (MelMarT-II). Ann Surg Oncol 2022;29:4050\u20134051."},{"key":"B10","series-title":"Ann Surg Oncol","first-page":"1959","article-title":"Melanoma of the vulva and vagina: principles of staging and their relevance to management based on a clinicopathologic analysis of 85 cases","volume":"22","author":"Seifried S","year":"2015","unstructured":"Seifried S, Haydu LE, Quinn MJ,  Melanoma of the vulva and vagina: principles of staging and their relevance to management based on a clinicopathologic analysis of 85 cases. Ann Surg Oncol 2015;22:1959\u20131966."},{"key":"B11","series-title":"Gynecol Oncol","first-page":"147","article-title":"Patient-reported outcomes after surgery for endometrial carcinoma: prevalence of lower-extremity lymphedema after sentinel lymph node mapping versus lymphadenectomy","volume":"156","author":"Leitao MM","year":"2020","unstructured":"Leitao MM, Zhou QC, Gomez-Hidalgo NR,  Patient-reported outcomes after surgery for endometrial carcinoma: prevalence of lower-extremity lymphedema after sentinel lymph node mapping versus lymphadenectomy. Gynecol Oncol 2020;156:147\u2013153."},{"key":"B12","series-title":"J Clin Oncol","first-page":"884","article-title":"Sentinel node dissection is safe in the treatment of early-stage vulvar cancer","volume":"26","author":"Van der Zee AGJ","year":"2008","unstructured":"Van der Zee AGJ, Oonk MH, De Hullu JA,  Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. J Clin Oncol 2008;26:884\u2013889."},{"key":"B13","series-title":"J Natl Compr Canc Netw","first-page":"364","article-title":"NCCN Guidelines Insights: Melanoma: Cutaneous, Version 2.2021","volume":"19","author":"Swetter SM","year":"2021","unstructured":"Swetter SM, Thompson JA, Albertini MR,  NCCN Guidelines Insights: Melanoma: Cutaneous, Version 2.2021. J Natl Compr Canc Netw 2021;19:364\u2013376."},{"key":"B14","series-title":"N Engl J Med","first-page":"1307","article-title":"Sentinel-node biopsy or nodal observation in melanoma","volume":"355","author":"Morton DL","year":"2006","unstructured":"Morton DL, Thompson JF, Cochran AJ,  Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006;355:1307\u20131317."},{"key":"B15","series-title":"N Engl J Med","first-page":"599","article-title":"Final trial report of sentinel-node biopsy versus nodal observation in melanoma","volume":"370","author":"Morton DL","year":"2014","unstructured":"Morton DL, Thompson JF, Cochran AJ,  Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med 2014;370:599\u2013609."},{"key":"B16","series-title":"N Engl J Med","first-page":"2211","article-title":"Completion dissection or observation for sentinel-node metastasis in melanoma","volume":"376","author":"Faries MB","year":"2017","unstructured":"Faries MB, Thompson JF, Cochran AJ,  Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med 2017;376:2211\u20132222."},{"key":"B17","series-title":"J Clin Oncol","first-page":"3000","article-title":"Final analysis of DeCOG-SLT trial: no survival benefit for complete lymph node dissection in patients with melanoma with positive sentinel node","volume":"37","author":"Leiter U","year":"2019","unstructured":"Leiter U, Stadler R, Mauch C,  Final analysis of DeCOG-SLT trial: no survival benefit for complete lymph node dissection in patients with melanoma with positive sentinel node. J Clin Oncol 2019;37:3000\u20133008."},{"key":"B18","series-title":"Lancet","first-page":"1718","article-title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomized, double-blind, phase 3 trial","volume":"399","author":"Luke JJ","year":"2022","unstructured":"Luke JJ, Rutkowski P, Queirolo P,  Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomized, double-blind, phase 3 trial. Lancet 2022;399:1718\u20131729."},{"key":"B19","series-title":"Lancet Oncol","first-page":"1378","article-title":"Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomized, phase 3 trial","volume":"23","author":"Long GV","year":"2022","unstructured":"Long GV, Luke J, Khattak MA,  Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomized, phase 3 trial. Lancet Oncol 2022;23:1378\u20131388."},{"key":"B20","series-title":"Clin Cancer Res","first-page":"4488","article-title":"Phase II randomized trial comparing high-dose IFN-\u03b12b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma","volume":"19","author":"Lian B","year":"2013","unstructured":"Lian B, Si L, Cui C,  Phase II randomized trial comparing high-dose IFN-\u03b12b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma. Clin Cancer Res 2013;19:4488\u20134498."},{"key":"B21","series-title":"Ann Oncol","first-page":"1061","article-title":"Toripalimab (anti-PD-1) versus high-dose interferon-\u03b12b as adjuvant therapy in resected mucosal melanoma: a phase II randomized trial","volume":"33","author":"Lian B","year":"2022","unstructured":"Lian B, Si L, Chi ZH,  Toripalimab (anti-PD-1) versus high-dose interferon-\u03b12b as adjuvant therapy in resected mucosal melanoma: a phase II randomized trial. Ann Oncol 2022;33:1061\u20131070."},{"key":"B22","series-title":"N Engl J Med","first-page":"1845","article-title":"Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy","volume":"375","author":"Eggermont AMM","year":"2016","unstructured":"Eggermont AMM, Chiarion-Sileni V, Grob JJ,  Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med 2016;375:1845\u20131855."},{"key":"B23","series-title":"J Clin Oncol","first-page":"567","article-title":"Phase III study of adjuvant ipilimumab (3 or 10 mg\/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma: North American Intergroup E1609","volume":"38","author":"Tarhini AA","year":"2020","unstructured":"Tarhini AA, Lee SJ, Hodi S,  Phase III study of adjuvant ipilimumab (3 or 10 mg\/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma: North American Intergroup E1609. J Clin Oncol 2020;38:567\u2013575."},{"key":"B24","series-title":"N Engl J Med","first-page":"1824","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber J","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M,  Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med 2017;377:1824\u20131835."},{"key":"B25","series-title":"Lancet Oncol","first-page":"1465","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB-IIIC and stage IV melanoma (CheckMate 238): 4-year results from a multicenter, double-blind, randomized controlled, phase III trial","volume":"21","author":"Ascierto PA","year":"2020","unstructured":"Ascierto PA, Del Vecchio M, Mandala M,  Adjuvant nivolumab versus ipilimumab in resected stage IIIB-IIIC and stage IV melanoma (CheckMate 238): 4-year results from a multicenter, double-blind, randomized controlled, phase III trial. Lancet Oncol 2020;21:1465\u20131477."},{"key":"B26","series-title":"J Clin Oncol","first-page":"3925","article-title":"Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: updated results from the EORTC 1325-MG\/KEYNOTE-054 trial","volume":"38","author":"Eggermont AMM","year":"2020","unstructured":"Eggermont AMM, Blank CU, Mandala M,  Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: updated results from the EORTC 1325-MG\/KEYNOTE-054 trial. J Clin Oncol 2020;38:3925\u20133936."},{"key":"B27","series-title":"N Engl J Med","first-page":"1139","article-title":"Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma","volume":"383","author":"Dummer R","year":"2020","unstructured":"Dummer R, Hauschild A, Santinami M,  Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma. N Engl J Med 2020;383:1139\u20131148."},{"key":"B28","series-title":"Ann Oncol","first-page":"1631","article-title":"Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E\/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study","volume":"28","author":"Long GV","year":"2017","unstructured":"Long GV, Flaherty KT, Stroyakovskiy D,  Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E\/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol 2017;28:1631\u20131639."},{"key":"B29","series-title":"J Surg Oncol","first-page":"111","article-title":"Does metastasectomy improve survival in patients with stage IV melanoma? A cancer registry analysis of outcomes","volume":"104","author":"Wasif N","year":"2011","unstructured":"Wasif N, Bagaria SP, Ray P,  Does metastasectomy improve survival in patients with stage IV melanoma? A cancer registry analysis of outcomes. J Surg Oncol 2011;104:111\u2013115."},{"key":"B30","series-title":"Ann Surg Oncol","first-page":"2547","article-title":"Metastasectomy for distant metastatic melanoma: analysis of data from the First Mulitcenter Selective Lymphadenectomy Trial (MSLT-I)","volume":"19","author":"Howard JH","year":"2012","unstructured":"Howard JH, Thompson JF, Mozzillo N,  Metastasectomy for distant metastatic melanoma: analysis of data from the First Mulitcenter Selective Lymphadenectomy Trial (MSLT-I). Ann Surg Oncol 2012;19:2547\u20132555."},{"key":"B31","series-title":"Cancer","first-page":"4740","article-title":"A phase 2 trial of complete resection for stage IV melanoma","volume":"117","author":"Sosman JA","year":"2011","unstructured":"Sosman JA, Moon J, Tuthill RJ,  A phase 2 trial of complete resection for stage IV melanoma. Cancer 2011;117:4740\u20134746."},{"key":"B32","series-title":"Ann Surg Oncol","first-page":"5005","article-title":"Surgical utilization and outcomes for patients with stage IV melanoma in the modern immunotherapy era","volume":"30","author":"Lwin TM","year":"2023","unstructured":"Lwin TM, Kaelberer Z, Ruan M,  Surgical utilization and outcomes for patients with stage IV melanoma in the modern immunotherapy era. Ann Surg Oncol 2023;30:5005\u20135012."},{"key":"B33","series-title":"Nat Med","first-page":"1655","article-title":"Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma","volume":"24","author":"Blank CU","year":"2018","unstructured":"Blank CU, Rozeman EA, Fanchi LF,  Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med 2018;24:1655\u20131661."},{"key":"B34","series-title":"Lancet Oncol","first-page":"948","article-title":"Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial","volume":"20","author":"Rozeman EA","year":"2019","unstructured":"Rozeman EA, Menzies AM, van Akkooi ACJ,  Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol 2019;20:948\u2013960."},{"key":"B35","series-title":"Ann Oncol","first-page":"420","article-title":"Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials","volume":"34","author":"Versluis JM","year":"2023","unstructured":"Versluis JM, Menzies AM, Sikorska K,  Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials. Ann Oncol 2023;34:420\u2013430."},{"key":"B36","series-title":"Nat Med","first-page":"1649","article-title":"Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma","volume":"24","author":"Amaria RN","year":"2018","unstructured":"Amaria RN, Reddy SM, Tawbi HA,  Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med 2018;24:1649\u20131654."},{"key":"B37","series-title":"N Engl J Med","first-page":"813","article-title":"Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma","volume":"388","author":"Patel SP","year":"2023","unstructured":"Patel SP, Othus M, Chen Y,  Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. N Engl J Med 2023;388:813\u2013823."},{"key":"B38","series-title":"Gynecol Oncol Rep","first-page":"42","article-title":"Combined immunotherapy and radiation for treatment of mucosal melanomas of the lower genital tract","volume":"16","author":"Schiavone MB","year":"2016","unstructured":"Schiavone MB, Broach V, Shoushtari AN,  Combined immunotherapy and radiation for treatment of mucosal melanomas of the lower genital tract. Gynecol Oncol Rep 2016;16:42\u201346."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/3\/article-e257081.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/3\/article-e257081.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/3\/article-e257081.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T12:31:25Z","timestamp":1773318685000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/3\/article-e257081.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":76,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2025.7081","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}